These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25656494)

  • 1. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.
    Quinkler M; Miodini Nilsen R; Zopf K; Ventz M; Øksnes M
    Eur J Endocrinol; 2015 May; 172(5):619-26. PubMed ID: 25656494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.
    Isidori AM; Venneri MA; Graziadio C; Simeoli C; Fiore D; Hasenmajer V; Sbardella E; Gianfrilli D; Pozza C; Pasqualetti P; Morrone S; Santoni A; Naro F; Colao A; Pivonello R; Lenzi A
    Lancet Diabetes Endocrinol; 2018 Mar; 6(3):173-185. PubMed ID: 29229498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.
    Gasco V; Giannelli J; Campioni L; Arvat E; Ghigo E; Grottoli S; Maccario M; Giordano R
    J Endocrinol Invest; 2023 Mar; 46(3):587-597. PubMed ID: 36251244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-release hydrocortisone improves body composition and the glucometabolic profile in patients with secondary adrenal insufficiency.
    Jørgensen NT; Boesen VB; Borresen SW; Christoffersen T; Jørgensen NR; Plomgaard P; Christoffersen C; Watt T; Feldt-Rasmussen U; Klose M
    Endocrine; 2024 Jun; 84(3):1182-1192. PubMed ID: 38345683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
    Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia.
    Merke DP; Mallappa A; Arlt W; Brac de la Perriere A; Lindén Hirschberg A; Juul A; Newell-Price J; Perry CG; Prete A; Rees DA; Reisch N; Stikkelbroeck N; Touraine P; Maltby K; Treasure FP; Porter J; Ross RJ
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2063-e2077. PubMed ID: 33527139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.
    Ekman B; Fitts D; Marelli C; Murray RD; Quinkler M; Zelissen PM
    BMC Endocr Disord; 2014 May; 14():40. PubMed ID: 24884782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrocortisone Dose Influences Pain, Depressive Symptoms and Perceived Health in Adrenal Insufficiency: A Randomized Controlled Trial.
    Werumeus Buning J; Brummelman P; Koerts J; Dullaart RP; van den Berg G; van der Klauw MM; Sluiter WJ; Tucha O; Wolffenbuttel BH; van Beek AP
    Neuroendocrinology; 2016; 103(6):771-8. PubMed ID: 26646751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency.
    Bannon CAM; Border D; Hanson P; Hattersley J; Weickert MO; Grossman A; Randeva HS; Barber TM
    Front Endocrinol (Lausanne); 2021; 12():641247. PubMed ID: 33776936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study.
    Guarnotta V; Di Stefano C; Tomasello L; Maniscalco L; Pizzolanti G; Arnaldi G; Giordano C
    Eur J Endocrinol; 2024 Aug; 191(3):300-311. PubMed ID: 39171906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.
    Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Ragnarsson O; Skrtic S; Wahlberg J; Achenbach H; Uddin S; Marelli C; Johannsson G
    Eur J Endocrinol; 2017 Jun; 176(6):715-725. PubMed ID: 28292927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis.
    Guarnotta V; Ciresi A; Pillitteri G; Giordano C
    Clin Endocrinol (Oxf); 2018 May; 88(5):665-672. PubMed ID: 29368442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
    Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Impact of Short- and Long-Term Hydrocortisone Replacement on Cognitive Function, Quality of Life and Catecholamine Secretion: A Pilot Study.
    Harbeck B; Danneberg S; Rahvar AH; Haas CS; Lehnert H; Kropp P; Mönig H
    Appl Psychophysiol Biofeedback; 2016 Sep; 41(3):341-7. PubMed ID: 27170300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.